Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
Tweet Send to a Friend
Baird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
